BNC-210
BNC210 is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor, by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder. The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials.
It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.
Phase I trials have shown no serious side effects.
Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States, but in November 2014, was released back to Bionomics in a mutual agreement. Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.
As of April 2015, BNC210 is in phase II clinical trials. The estimated study completion date is September 2018.Study Details
The clinical trial is currently testing twice daily oral dosages of 600 mg, 300 mg, and 150 mg, for 12 weeks. The primary objective of the trial is for the treatment of PTSD with a secondary objective for the effectiveness in treating anxiety disorders and depression.
